A fecal transplant (fecal microbiota transplantation, or FMT) moves screened stool from a healthy donor into a patient's gut to change the bacteria living there. It is a proven treatment for one infection, recurrent C. difficile, and an experimental idea for SIBO (small intestinal bacterial overgrowth), where only one small randomized trial exists. If you are wondering whether it could work for you, the honest answer is that nobody knows yet, and the safest place to find out is inside a registered clinical trial.
This article is for information only. It is not medical advice, and nothing here is a recommendation to have, or to avoid, any treatment. Decisions about SIBO treatment belong with your gastroenterologist.
What is a fecal transplant, and what is it actually approved for?
FMT is the transfer of processed stool from a screened donor into another person's gut. In the United States, the FDA has approved fecal-microbiota products only for preventing recurrence of C. difficile infection in adults after antibiotic treatment: Rebyota, given rectally, and Vowst, given as oral capsules (FDA 2023; Lee 2023).
That approval rests on strong evidence in a very specific setting. In the landmark Dutch trial, 13 of 16 people with recurrent C. difficile (81%) had their diarrhea resolve after a first donor-feces infusion, compared with 4 of 13 (31%) on vancomycin alone and 3 of 13 (23%) on vancomycin with bowel lavage, and the trial was stopped early because the difference was so large (van Nood 2013). A later randomized trial of an oral purified-spore product, SER-109, also tested the idea in recurrent C. difficile (Feuerstadt 2022).
C. difficile is a useful comparison because it is a near-ideal target. The infection thrives when antibiotics have wiped out the normal community, so replacing that community is a logical fix. SIBO is different: the problem is usually not too few bacteria but too many in the wrong place, often because of slow motility, past surgery or a structural change. That difference is why a result in one condition cannot simply be borrowed for the other.
Is fecal transplant FDA approved for SIBO?
No. There is no FDA-approved fecal transplant for SIBO, IBS or any condition other than recurrent C. difficile. The FDA's enforcement policy, finalized in November 2022, covers FMT only for C. difficile infection that has not responded to standard therapies, and it does not apply to FMT obtained from a stool bank (FDA 2022).
In plain terms, FDA treats FMT as a biological product. Using it for anything other than the approved C. difficile indication is normally expected to happen under an investigational new drug application, which means a registered study with oversight. That is the real answer to the Reddit claim that regulators "banned" capsules: there is no blanket ban on research, but there is also no approved pathway to buy FMT for SIBO. Be wary of anyone who tells you otherwise.
The policy position outside the US varies, and we have not verified every country, so if you live outside the US, ask your gastroenterologist what applies locally.
Does any research show FMT works for SIBO?
Only a little, and it is early. We found one randomized, placebo-controlled trial, a handful of small pilot or case reports, and no guideline that recommends FMT for SIBO. The randomized trial (55 patients) reported improvement in gastrointestinal symptoms with FMT capsules compared with placebo, but it has important limits (Xu 2021).
The details matter, so here is what that trial was. Patients at one hospital in Chongqing, China, were randomized to FMT capsules or placebo capsules once a week for four weeks, and were followed at 1, 3 and 6 months, with symptom scores, lactulose breath tests and stool microbiota analysis. The FMT group improved more on symptom scales, one person in that group had short-lived diarrhea, and no serious adverse events occurred. The authors themselves list limits: a single donor, a gut microbiota analysis they describe as "not ideal", and a need for larger trials with longer follow-up. The trial was also registered retrospectively, in July 2019 after enrollment ran from 2016 to 2018, which is a recognized weakness because it allows outcomes to be chosen after the fact.
A few other pieces of evidence exist:
- A case series. A Finnish report on people given FMT for conditions other than C. difficile included one person with SIBO who reported fewer symptoms. One patient is an anecdote, not evidence (Lahtinen 2017).
- A study in constipation. Among 218 people with chronic constipation who received FMT, those who also had SIBO on breath testing responded better than those without it. That study was not about treating SIBO, and it was not randomized for that question (Wang 2024).
- A caution from the other direction. In a pilot of 20 people receiving FMT for C. difficile, a positive breath test in the recipient did not predict outcome, but there was a non-significant trend toward more gastrointestinal symptoms after receiving stool from breath-test-positive donors (50% versus 14.2%, p = 0.09). The authors said larger studies are needed (Allegretti 2018).
Two further SIBO trials appear on the ClinicalTrials.gov registry: a single-arm pilot of FMT in children at a Canadian hospital, planning to enroll about 20, and a completed single-group study of 66 people in Shanghai, with no results we could verify (ClinicalTrials.gov). Registered does not mean effective; it only means the question is being studied.
Putting it together: a promising signal from one small trial, not yet repeated by an independent group, in a condition where the diagnosis itself is debated. Our guide to whether SIBO is a real condition covers why breath-test results are an imperfect outcome measure, which matters here because several of these studies used breath tests to define success. For the same reason, the post on a negative SIBO breath test with ongoing symptoms is worth reading before you compare any study's "response rate" to your own situation.
What do the IBS fecal transplant trials show?
They disagree, and that is the central fact. Randomized trials in IBS have produced everything from large benefits to a clear advantage for placebo, and the most recent pooled analysis calls the evidence very uncertain. Because many people with SIBO also carry an IBS label, these trials are the closest large body of evidence, even though they are not about SIBO.
| Trial | People and route | Main result | Takeaway |
|---|---|---|---|
| Johnsen 2018 | 83 analyzed, IBS with diarrhea or mixed, colonoscopic infusion | 65% responded with FMT versus 43% with placebo at 3 months (p = 0.049) | Modest benefit, no serious adverse events attributed to FMT |
| Halkjaer 2018 | 52 adults, moderate to severe IBS, 12 days of capsules | Placebo group improved more at 3 months; FMT changed the microbiota | Changing bacteria did not equal feeling better |
| El-Salhy 2020 | 165 adults, gastroscope delivery, one donor | Response 23.6% placebo, 76.9% with 30 g, 89.1% with 60 g | Strikingly positive; drew considerable published commentary and a single donor limits generalizing |
| Holvoet 2021 | Refractory IBS with bloating, nasojejunal route, 43 donor and 19 placebo | 56% versus 26% improved at 12 weeks (p = 0.03) | Benefit in some people, in a small trial |
The overall verdict comes from pooling these and others. A 2026 systematic review in Gastroenterology of 13 randomized trials with 693 people found that FMT may reduce IBS symptoms at 12 weeks, but the evidence was very uncertain (risk ratio of symptoms not improving 0.72, 95% confidence interval 0.50 to 1.03, which includes no effect). Per-protocol results were statistically significant, subgroups with a single dose or Rome IV diagnosis looked better, and adverse events were no more common than with placebo. The authors concluded that there was very low certainty evidence that FMT improved IBS symptoms and that the subgroup findings need cautious interpretation (Aumpan 2026).
Why would results differ so much? Trials used different donors, doses, routes (colonoscope, gastroscope, nasojejunal tube, capsules), IBS subtypes and placebo types, and placebo response rates in these trials were large (23.6% to 43%). The AGA's 2024 guideline weighed all this and suggested against conventional FMT for IBS or inflammatory bowel disease except in clinical trials, noting that FMT cannot yet be recommended outside C. difficile (Peery 2024). For the broader microbiome-product picture, see our guide to probiotics for IBS and the post on whether gut microbiome tests are worth it.
What are the risks of fecal transplant, and why is DIY FMT dangerous?
Most side effects of regulated FMT are mild, but serious infections do happen, and unscreened stool removes the main safeguard against them. A review of 129 studies covering 4,241 patients found adverse events in about 19% of procedures, mostly diarrhea (10%) and abdominal discomfort or cramping (7%), and serious adverse events in about 1.4% of patients (Marcella 2021).
That same review found that every serious FMT-related adverse event occurred in people with mucosal barrier injury, and that four of the five FMT-related deaths followed delivery through the upper gastrointestinal route. Both points matter for anyone with a damaged gut lining, such as active inflammatory bowel disease, and for anyone considering an upper-gut route, which is the route most often discussed for SIBO.
The most sobering case is documented in the New England Journal of Medicine. Two patients in two separate clinical trials developed bloodstream infections with extended-spectrum beta-lactamase-producing E. coli after FMT. Genomic sequencing traced both to the same stool donor, and one patient died (DeFilipp 2019). These were research programs that screened donors, and the transmission still happened. It prompted tighter donor testing requirements. FDA has also issued safety alerts about transmission risks, including SARS-CoV-2 (FDA 2020).
That is the argument against doing it yourself. A DIY kit, a friend or relative as donor, or a clinic with no registered protocol cannot offer the testing, tracking and reporting that a trial or an approved product carries. You also cannot see what is in stool. Bacteria, viruses, parasites and antibiotic-resistant organisms may all be present in a healthy-looking donor. We are not suggesting anyone pursue FMT outside a trial; if you have already been offered it by a clinic, our questions list below will help you check what you are being sold.
Why do some people feel it did nothing, or relapse?
Because SIBO often has an underlying cause, and FMT has not been shown to remove it. Even after standard antibiotics, breath tests turned positive again in 43.7% of 80 people within nine months in one study, and there are no long-term relapse data for FMT in SIBO. A common practical objection raised in r/SIBO threads, where a popular reply argues that FMT changes the bacterial community but not the functional problem underneath, so SIBO may return (r/SIBO discussion). That is a community's reasoning, not evidence, but it matches how clinicians think about the condition.
The ACG guideline defines SIBO as an excessive number of bacteria in the small bowel causing symptoms, and risk factors include things like slow motility, surgery and structural problems (Pimentel 2020). Relapse is common even after standard antibiotic treatment: in a study of 80 people who cleared SIBO on a one-week rifaximin course, breath tests turned positive again in 12.6% at 3 months, 27.5% at 6 months and 43.7% at 9 months, with older age, past appendectomy and long-term acid-suppressing medicine linked to recurrence (Lauritano 2008). We found no long-term relapse data for FMT in SIBO at all, so no one can say how it compares.
Other threads describe a different pattern: people who spent money on private FMT with no benefit, others who felt worse after a first round, and some who describe hoping for something that finally works. Those experiences are anecdotes, and they are consistent with the trial picture of "mixed results". If you are exhausted by this condition, that hope is understandable. It is also exactly the situation in which unregulated sellers do their business, so it is worth slowing down. For what to examine if symptoms return after treatment, see our post on why you can feel worse after SIBO treatment and the guide to improving motility with SIBO.
What is the standard treatment for SIBO instead?
The current standard is antibiotic treatment chosen by your prescriber, plus attention to any underlying cause. The ACG guideline covers antibiotic therapy for SIBO (Pimentel 2020), and rifaximin is the best-studied option: a meta-analysis of 32 studies and 1,331 patients found an overall eradication rate of about 71% with few adverse events (4.6%), though the authors rated study quality as generally poor and called for better trials (Gatta 2017).
We will not give regimens or doses here, and nothing in this article is a suggestion to start, stop or switch anything. Two other siblings in this series cover the wider options, including whether SIBO can be treated without antibiotics and whether oregano oil cures SIBO. Diet and gut-directed approaches are discussed in our SIBO diet versus low FODMAP comparison.
Two honest points belong here. First, the evidence for SIBO diagnosis and treatment is itself contested, which is why the ACG treats many statements as expert consensus rather than strong recommendations. Second, repeat courses and relapse are real problems, and that is exactly the gap that makes new ideas like FMT attractive. Being attracted to an unproven option is reasonable. Choosing it is a conversation to have with a gastroenterologist who knows your history.
How do you find a legitimate fecal transplant trial?
A legitimate trial is registered, ethically approved, run by an identifiable institution and does not charge you for the experimental treatment. Check each of these before saying yes to anything, and take the paperwork to your own gastroenterologist.
- Registry number. Search ClinicalTrials.gov (or the equivalent registry in your country) for the condition plus "fecal microbiota transplantation". A real trial has an identifier you can look up, a named sponsor and a stated plan.
- Ethics approval and informed consent. You should be given a written consent form describing the risks, including infection, and the right to withdraw.
- Donor screening. Ask how donors and stool are tested, and whether that testing includes drug-resistant organisms and viruses. This is the lesson from the infections described above.
- Who pays and who benefits. Trials generally do not charge participants for the study treatment. A price list, a package of "sessions" or a testimonial wall are marketing, not research.
- Placebo and follow-up. Ask whether you might receive placebo, how long you will be followed, and what is measured. The better trials above used a randomized placebo and followed people for months.
- Eligibility. Many trials exclude people with certain medicines, recent antibiotics or other conditions. A trial that says everyone is eligible deserves more questions, not fewer.
- Your own doctor. Ask your gastroenterologist whether the protocol fits your diagnosis and whether you are likely to be a good candidate.
What should you ask a clinic or trial team?
Write these down and ask them before you consent. Good answers are specific and willing to say "we don't know".
- Is this a registered clinical trial, and what is the registry number?
- Which condition has this exact product and route been tested in, and what were the results?
- How are donors screened, and when was the stool tested?
- What are the infection risks, and who do I contact if I develop a fever, severe pain or bloody diarrhea?
- Will you report results to the registry, whatever they are?
- What happens to my usual SIBO treatment during the trial, and who decides?
- What is not known about long-term effects?
How should you track symptoms if you join a trial?
Start a daily record two to four weeks before treatment and keep the same method throughout, because the whole point of a trial is comparing "before" with "after", and memory is poor at that. Without a record, it is easy to be unsure whether any change was real, which is what a good record is for.
Track the same few things every day:
- Bloating and pain on a 0 to 10 scale at set times (for example morning, mid-afternoon and evening), so a pattern of timing is visible.
- Stool form and frequency using the Bristol scale.
- Gas, nausea, reflux or urgency, whatever your main symptoms are.
- Everything that could change the picture: antibiotics, probiotics, new supplements, a big diet change, travel, stress, poor sleep, illness.
- Procedure dates and any breath test dates, so results can be lined up against how you felt.
- Anything unexpected after the procedure, especially fever or worsening pain, noted with the time and reported to the study team promptly.
Give the same scale to yourself that the trial uses, if it provides one. If the study uses a symptom questionnaire, fill it in as asked and keep your own diary alongside it rather than instead of it.
If you prefer a phone, Clairop is a free-to-download iPhone app that logs meals, bowel movements and symptoms and can turn them into a one-page report for a GI visit. A paper diary works just as well. Our guides to the symptom tracker for your doctor and how to prepare for a GI appointment show how to organize the record, and How it works explains what the app logs.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
A diary cannot tell you whether the treatment worked on its own. What it can do is show a clinician or study team that your average bloating score fell, stayed flat or crept back, and when. That distinction between "I felt better for a few weeks" and "I stayed better" is exactly what current SIBO research lacks.
What are the red flags that need a doctor promptly?
See a doctor promptly for blood in your stool, black stools, unexplained weight loss, persistent vomiting, fever, symptoms that wake you at night, pale greasy stools, anemia, symptoms that start after 50, or a family history of bowel cancer or inflammatory bowel disease. Do not attribute these to SIBO or wait for an experimental treatment.
If you develop fever, severe abdominal pain, bloody diarrhea or feel very unwell after any FMT procedure, seek urgent medical care and tell the treating team where and when you had it. Infections after FMT, though rare, can be serious and are treated as emergencies.
Common myths about FMT and SIBO
- "FMT resets the whole gut." The trials show that it changes the stool microbiota, but in one IBS trial that change did not bring better symptoms than placebo (Halkjaer 2018). Changing bacteria and feeling better are separate outcomes.
- "More donor stool is always better." One IBS trial linked a higher dose to a higher response, but it was a single-donor study and has not settled the question (El-Salhy 2020).
- "It is natural, so it must be safe." Natural stool can carry harmful organisms; screened trial stool has still transmitted a fatal infection (DeFilipp 2019).
- "The studies already prove it for SIBO." There is one small randomized trial and a few pilots, from which no guideline has yet drawn a recommendation.
- "Capsules and gastroscopy are equivalent." Routes differ in risk; the safety review linked most FMT-related deaths to the upper-gut route (Marcella 2021). Trials rarely compare routes head to head.
Which claims from Reddit could not be verified?
Several confident claims in SIBO forums have no support we could find, so we left them out of the advice above. These include that donor bacteria will not engraft unless SIBO or yeast overgrowth is cleared first, that a particular number of bacterial strains predicts who benefits, and that capsules were banned because of pharmaceutical lobbying. The last one is also hard to square with the existence of an FDA-approved oral product for C. difficile. Treat these as opinions until a trial tests them.
The bottom line
A fecal transplant is a real, approved treatment for recurrent C. difficile and an unproven experiment for SIBO. One small randomized trial is encouraging but not enough, the IBS trials are mixed, and the AGA advises against FMT for IBS outside research. Do-it-yourself and unregulated FMT are not safe substitutes. If the idea still appeals, talk to your gastroenterologist about a registered trial, ask the questions above, and keep a careful symptom record so that you, and the researchers, can see what actually changed.




